PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
11-Apr-2025 EVERSANA Unveils EVERSANA ORCHESTRATE™ MLR, an AI-Powered Solution to Transform the Medical, Legal & Regulatory Process EVERSANA
11-Apr-2025 MEDICAL BOOST FOR YOUNG MEN AS NEW, HIGHLY ACCURATE EARLY DETECTION TESTICULAR CANCER TEST LAUNCHED IN UK EDX Medical
11-Apr-2025 Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024 Eckert & Ziegler SE
11-Apr-2025 Gerresheimer: Bormioli Pharma boosts revenues and earnings Gerresheimer AG
10-Apr-2025 Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments Immunic AG
10-Apr-2025 SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations  SCHOTT Pharma AG & Co. KGaA
10-Apr-2025 Galenica Annual General Meeting approves all motions and elects new member of the Board of Directors Galenica AG
10-Apr-2025 FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures FamiCord AG
10-Apr-2025 Straumann Group shareholders approve all proposals Straumann Holding AG
10-Apr-2025 Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe SCHOTT Pharma AG & Co. KGaA
10-Apr-2025 Siegfried shareholders approve all proposals at Annual General Meeting 2025 Siegfried AG
10-Apr-2025 Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig Eckert & Ziegler SE
10-Apr-2025 Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP® VET for veterinary use Viromed Medical AG
10-Apr-2025 Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies Cellistic
10-Apr-2025 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update CureVac
10-Apr-2025 Evotec SE to announce results for financial year 2024 on 17 April 2025 Evotec SE
10-Apr-2025 NICE recommends BALVERSA®▼ (erdafitinib), the first and only treatment in the UK for metastatic or unresectable fibroblast growth factor receptor (FGFR3)-altered urothelial cancer (UC) for patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor Johnson & Johnson
10-Apr-2025 Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 2025 - for the first time more than EUR 10.7 million revenue in one month Cantourage Group SE
10-Apr-2025 Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 – for the first time more than EUR 10.7 million revenue in one month Cantourage Group SE
10-Apr-2025 Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria Marinomed Biotech AG